Skin and Other Melanoma

- Basal cell carcinoma
- BRAF-mutant melanoma
- Metastatic melanoma, not otherwise specified
- Kidney transplant recipients with melanoma, basal cell carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma or MSI-high cancer

**10057:** A Phase II Study of T-VEC Followed by T-VEC + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

**9466:** Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only)

**10214:** Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers

**10285:** Phase 1 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy

**9676:** A Phase 1 Trial of MK-3475 Plus Ziv- Afibercept in Patients with Advanced Solid Tumors (Expansion phase, Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 16, 2019